Tyra Biosciences, Inc. (NASDAQ:TYRA) Short Interest Update

Tyra Biosciences, Inc. (NASDAQ:TYRA) was the target of a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 5,100,000 shares, an increase of 17.2% from the April 30th total of 4,350,000 shares. Currently, 16.0% of the shares of the company are sold short. Based on an average daily volume of 319,800 shares, the short-interest ratio is presently 15.9 days.

Tyra Biosciences Price Performance

Tyra Biosciences stock opened at $10.17 on Friday. Tyra Biosciences has a one year low of $6.42 and a one year high of $29.60. The business has a fifty day moving average price of $9.28 and a 200-day moving average price of $12.21. The firm has a market capitalization of $539.93 million, a P/E ratio of -6.32 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Sell-side analysts expect that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TYRA has been the subject of several research reports. Wedbush reissued an “outperform” rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Friday, March 28th. Piper Sandler initiated coverage on Tyra Biosciences in a report on Wednesday, May 21st. They set an “overweight” rating and a $33.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, March 31st. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $30.83.

Hedge Funds Weigh In On Tyra Biosciences

A number of large investors have recently made changes to their positions in the stock. Rhumbline Advisers boosted its holdings in shares of Tyra Biosciences by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock worth $364,000 after acquiring an additional 1,027 shares during the period. American Century Companies Inc. raised its position in shares of Tyra Biosciences by 5.8% in the first quarter. American Century Companies Inc. now owns 23,431 shares of the company’s stock worth $218,000 after buying an additional 1,289 shares in the last quarter. US Bancorp DE raised its position in shares of Tyra Biosciences by 50.5% in the first quarter. US Bancorp DE now owns 5,435 shares of the company’s stock worth $51,000 after buying an additional 1,823 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Tyra Biosciences in the fourth quarter worth $31,000. Finally, Bank of New York Mellon Corp raised its position in shares of Tyra Biosciences by 5.2% in the fourth quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company’s stock worth $626,000 after buying an additional 2,221 shares in the last quarter. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.